IDH-mutant glioma
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
7 of 9 arms with a reported figure. Choose arms to narrow the chart.
| Drug, trial | Population | Dose | Estimand | Comparator | ORR, % | mPFS, months | mOS, months | Hazard ratio | Other |
|---|---|---|---|---|---|---|---|---|---|
| Vorasidenib 40 mgINDIGO | grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163) | 40 mg | ITT | placebo | objective response rate, extended follow-up: 20.8%, ASCO 2026, preliminary | median PFS, vorasidenib: 27.7 months, NEJM 2023median PFS, placebo: 11.1 months, NEJM 2023median PFS, extended follow-up: 44.1 months, ASCO 2026, preliminary | n/r | PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysistime to next intervention hazard ratio: 0.26 HR, primary analysis | median time to next intervention, placebo: 17.8 months, primary analysis |
| Vorasidenib Phase 1 dosesVorasidenib Phase 1 | recurrent non-enhancing IDH-mutant glioma (n = 22) | Phase 1 doses | Single arm | n/r | objective response rate: 18%, Phase 1 | median PFS: 36.8 months, Phase 1 | n/r | n/r | n/r |
| Safusidenib (AB-218, DS-1001) 250 mgJ201 Phase 2 | IDH1-mutant grade 2 glioma, Japan (n = 27 per company; registry n = 25) | 250 mg | Single arm | n/r | confirmed objective response rate: 51.9%, median follow-up 38.8 months | 36-month PFS rate: 79.1%, median follow-up 38.8 months | n/r | n/r | n/r |
| Olutasidenib 150 mgOlutasidenib Phase 1/2 (glioma cohort) | relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable) | 150 mg | Single arm | n/r | objective response rate: 8%, 2 of 25 | n/r | n/r | n/r | disease control rate: 48%, 12 of 25 |
| Ivosidenib Phase 1 dosesIvosidenib Phase 1 (glioma) | recurrent non-enhancing IDH1-mutant glioma | Phase 1 doses | Single arm | n/r | n/r | median PFS: 13.6 months, 95% CI 9.2 to 33.2 | n/r | n/r | n/r |
| IDH1-VAC (IDH1 R132H Peptide Vaccine) not stated in sourceNOA-16 | newly diagnosed IDH1 R132H astrocytoma | not stated in source | Single arm | n/r | n/r | 3-year PFS rate: 63% | n/r | n/r | vaccine-induced immune response: 93.3%, 28 of 30 evaluable |
| Olaparib 300 mgOLAGLI | recurrent IDH-mutant high-grade glioma (n = 35) | 300 mg | Single arm | n/r | n/r | 6-month PFS rate: 31.4%, primary endpoint, target 50% not metmedian PFS: 2.05 months | median OS: 15.9 months | n/r | n/r |
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.